Evidence map›Paper›PMID 27629595›Full record

ArticleCancer immunology, immunotherapy : CII2016

Macrophage migration inhibitory factor (MIF) is induced by cytotoxic drugs and is involved in immune escape and migration in childhood rhabdomyosarcoma.

Sarah Maria Johler, Jörg Fuchs, Guido Seitz, Sorin Armeanu-Ebinger

Open access · greenAbstract read
In one paragraph

Article in Cancer immunology, immunotherapy : CII, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Sulforaphane activates CD8Journal for immunotherapy of cancer · 2024
    Article
  4. Article
  5. Article
  6. Article
  7. MIF-Dependent Control of Tumor Immunity.Frontiers in immunology · 2020
    Review
  8. Review
  9. Review
  10. Article
  11. Oral squamous carcinoma cells promote macrophage polarization in an MIF-dependent manner.QJM : monthly journal of the Association of Physicians · 2018
    Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Sarah Maria JohlerDepartment of Pediatric Surgery and Urology, University Children's Hospital Tübingen, Hoppe-Seyler-Str. 3, 72076, Tübingen, Germany.
Jörg FuchsDepartment of Pediatric Surgery and Urology, University Children's Hospital Tübingen, Hoppe-Seyler-Str. 3, 72076, Tübingen, Germany.
Guido SeitzDepartment of Pediatric Surgery and Urology, University Children's Hospital Tübingen, Hoppe-Seyler-Str. 3, 72076, Tübingen, Germany.
Sorin Armeanu-EbingerDepartment of Pediatric Surgery and Urology, University Children's Hospital Tübingen, Hoppe-Seyler-Str. 3, 72076, Tübingen, Germany. armeanu@uni-tuebingen.de.
University Children's Hospital Tübingen · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Macrophage migration inhibitory factor (MIF) is known to be involved in oncogenic transformation, tumour progression, and immunosuppression and is overexpressed in many solid tumours, including paediatric rhabdomyosarcoma (RMS). We investigated the function of MIF in RMS during treatment with cytotoxic drugs. RMS cell lines were analysed by flow cytometry, immunofluorescence staining, and ELISA. We demonstrated the overexpression of MIF in RMS cells and the enhanced expression and secretion after treatment with cytotoxic agents. Migration assays of RMS cells revealed that inhibitors of MIF (ISO-1, Ant.III 4-IPP, Ant.V, sulforaphane (SF)) and blocking antibodies caused reduced migration, indicating a role for MIF in metastatic invasion. Additionally, we investigated the function of MIF in immune escape. The development of a population containing immunosuppressive myeloid-derived suppressor cells was promoted by incubation in conditioned medium of RMS cells comprising MIF and was reversed by MIF inhibitors but not by antibodies. Although most inhibitors may restore immune activity, Ant.III and 10 µM SF disturbed T cell proliferation in a CFSE assay, whereas T cell proliferation was not reduced by 3 µM SF, ISO-1 or antibodies. However, the inhibition of MIF by blocking antibodies did not increase the killing activity of allogenic PBMCs co-cultured with RMS cells. Our results reveal that MIF may be involved in an immune escape mechanism and demonstrate the involvement of MIF in immunogenic cell death during treatment with cytotoxic drugs. Targeting MIF may contribute to the restoration of immune sensitivity and the control of migration and metastatic invasion.

Indexed as

Antineoplastic AgentsHumansImmunotherapyMacrophage Migration-Inhibitory FactorsRhabdomyosarcomaAntineoplastic AgentsMacrophage Migration-Inhibitory FactorsImmune escape and surveillanceImmunotherapyMacrophage migration inhibitory factor (MIF)MDSCsMIF inhibitorsRhabdomyosarcoma

Identifiers

PMID27629595
PMCPMC11029580
OpenAlexW2519554108

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.